Results 101 to 110 of about 85,538 (123)

Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis

European Urology Focus
Despite its well-established role in metastatic renal cell carcinoma (mRCC), the optimal timing of cytoreductive nephrectomy (CN) is unclear. The aim of this systematic review is to compare the overall survival (OS) between upfront (uCN) and deferred (dCN) CN.The MEDLINE, EMBASE, and Web of Science databases were queried (end of search date: August 26,
Stepan M, Esagian, Jose A, Karam, Pavlos, Msaouel, Dimitrios, Makrakis   +3 more
exaly   +3 more sources

Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.

Journal of Clinical Oncology, 2016
607 Background: Since 2005 seven new agents were approved for metastatic renal cell carcinoma (mRCC), demarcating a transition from the cytokine to the targeted therapy era. Trials demonstrated a survival benefit for upfront cytoreductive nephrectomy (CN) pre-2005.
Liam Connor Macleod, Scott S. Tykodi, Sarah Holt, John L. Gore   +3 more
openaire   +1 more source

Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.

Journal of Clinical Oncology
502 Background: Deferred cytoreductive nephrectomy (dCN) is an emerging, strategy in the management of metastatic renal cell carcinoma (mRCC), applied selectively to patients who demonstrate a favorable response to initial systemic therapy.
Patricia Rioja, Carolina Passarella, Martin Angel, Wbeimar Valderrama, Freya Bosma, Georgia Anguera, Victoria Gomez, Álvaro Ruiz-Granados, David Plata, Martin Ignacio Zapata Laguado, Alberto Orta-Ruiz, Maria Natalia Gandur-Quiroga, Maria T. Bourlon, Enrique Grande, Ray Manneh, Javier Molina-Cerrillo, Pablo Maroto-Rey, Juan Pablo Sade, Daniel Castellano   +18 more
openaire   +1 more source

Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy

European Urology, 2021
J. Choy, B. Szabados, Y. Abu-Ghanem, T. Powles, A. Wimalasingham, A. Bex   +5 more
openaire   +1 more source

Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study

Urologic Oncology: Seminars and Original Investigations
Deferred cytoreductive nephrectomy (dCN) is a selective strategy for managing metastatic renal cell carcinoma (mRCC), in the era of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI), particularly for patients who achieve favorable responses to initial systemic therapy.
Patricia Rioja, Carolina Passarella, Martín Angel, Wbeimar Valderrama, Freya Bosma Ainaud, Georgia Anguera, Victoria Gómez, Álvaro Ruiz-Granados, David Plata, Martín Ignacio Zapata, Alberto Orta-Ruiz, María N. Gandur Quiroga, Maria T. Bourlon, Enrique Grande, null Ray Manneh Kopp, Javier Molina-Cerrillo, Pablo Maroto, Juan Pablo Sade, Daniel Castellano   +18 more
openaire   +3 more sources

Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval?

European Urology, 2023
E.E. Fransen van de Putte, L. Van Den Brink, M. Mansour, J.C. Van Der Mijn, S. Wilgenhof, J.V. Van Thienen, J.B.A. Haanen, E. Boleti, T. Powles, P.J. Zondervan, N.M. Graafland, A. Bex   +11 more
openaire   +1 more source

Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications

World Journal of Urology
To evaluate the incidence of postoperative complications after cytoreductive nephrectomy (CN) following first-line treatment for metastatic renal cell carcinoma (mRCC), and to compare it with postoperative complications of upfront CN.For this population-based retrospective study, the PearlDiver Mariner database (PearlDiver Technologies, Colorado ...
Ditonno F, Bologna E, Licari LC, Franco A, Pettenuzzo G, Leonardo C, Proietti F, Carbonara U, Mir MC, Crivellaro S, Veccia A, Bertolo R, Antonelli A, Autorino R   +13 more
openaire   +4 more sources

Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?

European urology oncology, 2020
n ...
Mollica V., Rizzo A., Massari F.
openaire   +2 more sources

Characterization of Patients With Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

European Urology Oncology
The role of cytoreductive nephrectomy (CN) has not yet been well characterized in the era of combination immunotherapy.To evaluate characteristics and outcomes for patients with metastatic renal cell carcinoma (mRCC) who received immuno-oncology (IO)-based combination therapy according to CN status.Using the International mRCC Database Consortium (IMDC)
Kosuke Takemura, D Scott Ernst, J Connor Wells   +2 more
exaly   +5 more sources

Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.

Journal of Clinical Oncology
468 Background: The role of cytoreductive nephrectomy (CN) in patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor (ICI)-based therapies remains under debate.
Paulo Siqueira do Amaral, Katy Beckermann, Gabriel Berlingieri Polho, Kelvin A. Moses, Jennifer B. Gordetsky, Sam S. Chang, Amy Luckenbaugh, Kristin Kathleen Ancell, Morgan Lambrecht, Kerry Roe Schaffer, Elizabeth Kaiser, Daniel D. Joyce, Brian I. Rini   +12 more
openaire   +1 more source